Related references
Note: Only part of the references are listed.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PI3K/Akt Pathway Mutations in Retinoblastoma
Yoram Cohen et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-line Therapy for Patients With Advanced Pancreatic Cancer
Henry Q. Xiong et al.
CANCER (2008)
Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors
Elizabeth Buck et al.
CANCER RESEARCH (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation
T Asano et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AN1424) to prevent chemotherapy induced peripheral neuropathy
ID Davis et al.
CLINICAL CANCER RESEARCH (2005)
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells
T Asano et al.
ONCOGENE (2004)
Targeting the molecular target of rapamycin (mTOR)
EK Rowinsky
CURRENT OPINION IN ONCOLOGY (2004)
Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors
DW Davis et al.
CLINICAL CANCER RESEARCH (2004)
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study
ML Rothenberg et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
